Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    Novel Antimicrobials for Killing Anthrax

    By Global Biodefense StaffJune 7, 2012
    Share
    Facebook LinkedIn Reddit Email

    The CDC’s Division of High-Consequence Pathogens and Pathology (DHCPP) Bacterial and Special Pathogens Branch this week announced its intent to issue a purchase order to the University of Michigan Life Sciences Institute for the production of novel antimicrobials for specific killing of Bacillus anthracis.

    Despite the problem of bacteria becoming increasingly resistant to the current arsenal of therapeutic agents, few novel classes of antimicrobials have been discovered.  In addition to naturally acquired resistance, there is increasing concern that engineered, multi-drug resistant (MDR) strains could be used in a bioterrorism event.  According to the CDC, such an occurrence could greatly limit or eliminate their ability to effectively treat diseases such as anthrax, where early administration of appropriate antimicrobials is critical for care and a positive patient outcome.

    One approach in recent years has been to use anti-sense oligonucleotides (oligos) to target specific mRNA to inhibit bacterial growth. Although the anti-sense approach has been used since the 1970s, several developments have led to more recent success. First was the development of morpholino oligos, which are resistant to ribonucleases, and thus more stable. Second was the addition of membrane-penetrating peptides to morpholino oligos in order to increase uptake and effectively kill bacteria.

    The planned effort involves using morpholino oligos linked to Bacillus anthracis siderophores to treat anthrax. The siderophores bind iron and the iron-siderophore complex is then transported across the cell envelope into the cell. The siderophore would act as a “Trojan horse” and lead to the active uptake of the drug, and approach that has been used successfully with traditional antibiotics.

    Work to generate a new class of antimicrobial agents will focus on generating a modified form of the virulence factor petrobactin that is covalently modified with an anti-sense morpholino oligonucleotide. The process requires the development of a method to conjugate a morpholino-oligonucleotide to the siderophore. This molecule would be recognized by receptors on the cell surface of the bacteria, and internalized where the covalently linked antisense oligonucleotide would bind to its complimentary strand of RNA blocking translation of genes necessary for growth.

    Such a process could be applied as a means of killing other pathogenic bacteria and used as a therapeutic in the case of organisms with resistance to currently used antibiotics.

    The contract effort is managed under Solicitation Number: 00HCVLEG-2012-43251.

    Anthrax Antimicrobials Bioterrorism
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDoD Influenza Surveillance Support Contract Awarded in Thailand
    Next Article USDA Begins Routine Testing for Non-O157 STEC

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.